Table 1 Multivariate cox regression analysis of 72 patients with MCL who have undergone autoSCT

From: Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma

 

PFS from autoSCT

OS from autoSCT

 

P

HR

P

HR

Rituximab maintenance

0.02

0.23 (0.06–0.80)

0.51

0.61 (0.14–2.65)

Year of transplant (beginning from 2000)

0.79

0.97 (0.83–1.14)

0.43

0.90 (0.69–1.16)

Age (per 10 years)

0.96

1.00 (0.95–1.05)

0.29

1.51 (0.69–3.30)

Remission prior autoSCT (non-CR vs CR)

0.24

1.58 (0.73–3.47)

0.41

1.64 (0.51–5.26)

HD-ARA treatment

0.63

0.69 (0.16–3.12)

0.96

0.94 (0.08–11.1)

Upfront autoSCT

0.80

0.81 (0.17–3.97)

0.72

0.64 (0.05–7.75)

  1. Abbreviations: autoSCT, autologous stem cell transplantation; CR, complete response; HR, hazard ratio; MCL, Mantle cell lymphoma; OS, overall survival; PFS, progression-free survival.
  2. Twenty-two patients received rituximab maintenance and 50 patients did not receive any further treatment.
Back to article page